Multiple Myeloma in Relapse Recruiting Phase 2 Trials for Elotuzumab (DB06317)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03030261Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaTreatment
NCT03155100Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesTreatment